Valuation: Silence Therapeutics plc

Market Cap 43Cr 57Cr 51Cr 48Cr 82Cr 5.55TCr 82Cr 573.3Cr 224.23Cr 2.82TCr 215.21Cr 210.54Cr 9.07TCr P/E 2026 *
-17.9x
P/E 2027 * -14.4x
Enterprise Value 30Cr 40Cr 35Cr 33Cr 57Cr 3.85TCr 57Cr 397.39Cr 155.43Cr 1.96TCr 149.18Cr 145.94Cr 6.29TCr EV / Sales 2026 *
932x
EV / Sales 2027 * 346x
Free-Float
69.35%
Yield 2026 *
-
Yield 2027 * -
1 day-3.05%
1 week-11.11%
Current month-12.90%
1 month-30.46%
3 months-4.32%
6 months+62.74%
Current year+56.58%
1 week 9.06
Extreme 9.055
10.65
1 month 9.06
Extreme 9.055
13.81
Current year 4.19
Extreme 4.19
17.58
1 year 4.19
Extreme 4.19
17.58
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 01/12/2025
Director of Finance/CFO 54 01/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/01/2004
Director/Board Member 65 05/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
06/07/26 Sell 8,65,112 0.6105%
02/01/26 Free

Chief Financial Officer

3,75,000 0.2646%
02/01/26 Free

Director

90,000 0.0635%
Change 5-day change 1-year change 3-year change Capi.($)
-3.05%-11.11%+81.33%+1.28% 57Cr
-3.19%-3.19%+44.60%+87.98% 7.21TCr
-15.86%-16.16%+2.68%+50.90% 4.94TCr
-2.39%+0.50%+3.41%+31.33% 4.72TCr
-6.35%-8.63%+293.39%+651.28% 4.03TCr
+0.30%-0.71%+29.05%+30.33% 4.26TCr
-3.82%-2.41%-0.27%+101.36% 3.98TCr
-2.13%-2.18%+7.51%+50.31% 3.05TCr
-3.35%-4.95%-13.38%-17.22% 2.31TCr
-5.27%+1.86%+12.19%-5.34% 2.11TCr
Average -4.51%-4.40%+46.05%+98.22% 3.67TCr
Weighted average by Cap. -4.85%-3.86%+45.77%+117.09%

Financials

2026 *2027 *
Net sales 3L 4L 4L 4L 6L 4.13Cr 6L 42.62L 16.67L 2.1Cr 16L 15.65L 6.74Cr 8L 10L 9L 8L 14.12L 9.61Cr 14.26L 99.2L 38.8L 4.88Cr 37.24L 36.43L 16Cr
Net income -4.21Cr -5.57Cr -4.97Cr -4.64Cr -7.93Cr -539.26Cr -8.01Cr -56Cr -22Cr -274.03Cr -21Cr -20Cr -881.28Cr -7.1Cr -9.38Cr -8.38Cr -7.82Cr -13Cr -908.81Cr -13Cr -94Cr -37Cr -461.81Cr -35Cr -34Cr -1.49TCr
Net Debt -13Cr -18Cr -16Cr -15Cr -25Cr -1.7TCr -25Cr -175.91Cr -69Cr -865.56Cr -66Cr -65Cr -2.78TCr -17Cr -23Cr -21Cr -19Cr -33Cr -2.23TCr -33Cr -230.02Cr -90Cr -1.13TCr -86Cr -84Cr -3.64TCr
Projected Income Statement - Annual - Silence Therapeutics plc
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
08/26/08 $9.520 -3.05% 11,09,565
07/26/07 $9.820 -0.10% 13,19,570
06/26/06 $9.830 -3.06% 15,83,356
05/26/05 $10.14 -4.70% 9,76,296
02/26/02 $10.64 -0.65% 9,73,327
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Silence Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.520USD
Average target price
33.00USD
Spread / Average Target
+246.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Silence Therapeutics plc